QUIZ: What Percentage of Phase 1 Medications Become FDA Approved?

Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.

The 4-day CME meeting in Las Vegas offers up to 24.25 credits and sessions on inflammatory skin disease, skin cancer, pediatric dermatology, aesthetics, and more.

A biopsy-based analysis from the JADE MOA trial presented at EADV 2026 found reductions in pathogenic skin-resident memory T cells alongside restoration of epidermal barrier integrity.

Explore dermatology conferences and meetings taking place this October, including clinical updates, skin of color education, and pediatric dermatology research.

From next-generation oral therapies and long-term disease control to precision medicine, EADV 2026 highlighted a dermatology landscape increasingly focused on deeper, durable, and individualized outcomes.

The final day of EADV 2026 explored precision medicine, molecular profiling, atopic dermatitis research, real-world evidence, and emerging approaches to individualized dermatologic care.

New EADV 2026 data highlighted real-world outcomes in adults with chronic hand eczema and improvements in itch, pain, and quality of life among adolescents treated with delgocitinib cream.

Day 3 of EADV 2026 featured long-term psoriasis data, advances in hidradenitis suppurativa, evolving approaches to atopic dermatitis, and late-breaking research.